AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues

EMA

31 March 2021 - EMA’s safety committee (PRAC) is meeting today in the context of its ongoing review of very rare cases of unusual blood clots associated with low numbers of platelets, in people vaccinated with AstraZeneca’s COVID-19 vaccine (now called Vaxzevria).

EMA convened an ad hoc expert group meeting on Monday 29 March to provide further input into the ongoing assessment.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Europe , Vaccine , Safety , COVID-19